411 related articles for article (PubMed ID: 12456232)
1. Diabetes, plasma insulin, and cardiovascular disease: subgroup analysis from the Department of Veterans Affairs high-density lipoprotein intervention trial (VA-HIT).
Rubins HB; Robins SJ; Collins D; Nelson DB; Elam MB; Schaefer EJ; Faas FH; Anderson JW
Arch Intern Med; 2002 Dec 9-23; 162(22):2597-604. PubMed ID: 12456232
[TBL] [Abstract][Full Text] [Related]
2. Relation of gemfibrozil treatment and lipid levels with major coronary events: VA-HIT: a randomized controlled trial.
Robins SJ; Collins D; Wittes JT; Papademetriou V; Deedwania PC; Schaefer EJ; McNamara JR; Kashyap ML; Hershman JM; Wexler LF; Rubins HB;
JAMA; 2001 Mar; 285(12):1585-91. PubMed ID: 11268266
[TBL] [Abstract][Full Text] [Related]
3. Insulin resistance and cardiovascular events with low HDL cholesterol: the Veterans Affairs HDL Intervention Trial (VA-HIT).
Robins SJ; Rubins HB; Faas FH; Schaefer EJ; Elam MB; Anderson JW; Collins D;
Diabetes Care; 2003 May; 26(5):1513-7. PubMed ID: 12716814
[TBL] [Abstract][Full Text] [Related]
4. Gemfibrozil for secondary prevention of cardiovascular events in mild to moderate chronic renal insufficiency.
Tonelli M; Collins D; Robins S; Bloomfield H; Curhan GC;
Kidney Int; 2004 Sep; 66(3):1123-30. PubMed ID: 15327407
[TBL] [Abstract][Full Text] [Related]
5. Cardiovascular events with increased lipoprotein-associated phospholipase A(2) and low high-density lipoprotein-cholesterol: the Veterans Affairs HDL Intervention Trial.
Robins SJ; Collins D; Nelson JJ; Bloomfield HE; Asztalos BF
Arterioscler Thromb Vasc Biol; 2008 Jun; 28(6):1172-8. PubMed ID: 18356553
[TBL] [Abstract][Full Text] [Related]
6. Rationale and design of the Department of Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial (HIT) for secondary prevention of coronary artery disease in men with low high-density lipoprotein cholesterol and desirable low-density lipoprotein cholesterol.
Rubins HB; Robins SJ; Iwane MK; Boden WE; Elam MB; Fye CL; Gordon DJ; Schaefer EJ; Schectman G; Wittes JT
Am J Cardiol; 1993 Jan; 71(1):45-52. PubMed ID: 8420235
[TBL] [Abstract][Full Text] [Related]
7. Body weight, plasma insulin, and coronary events with gemfibrozil in the Veterans Affairs High-Density Lipoprotein Intervention Trial (VA-HIT).
Robins SJ; Collins D; McNamara JR; Bloomfield HE
Atherosclerosis; 2008 Feb; 196(2):849-55. PubMed ID: 17335828
[TBL] [Abstract][Full Text] [Related]
8. Cost-effectiveness of gemfibrozil for coronary heart disease patients with low levels of high-density lipoprotein cholesterol: the Department of Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial.
Nyman JA; Martinson MS; Nelson D; Nugent S; Collins D; Wittes J; Fye CL; Wilt TJ; Robins SJ; Bloomfield Rubins H;
Arch Intern Med; 2002 Jan; 162(2):177-82. PubMed ID: 11802751
[TBL] [Abstract][Full Text] [Related]
9. Reduction in stroke with gemfibrozil in men with coronary heart disease and low HDL cholesterol: The Veterans Affairs HDL Intervention Trial (VA-HIT).
Bloomfield Rubins H; Davenport J; Babikian V; Brass LM; Collins D; Wexler L; Wagner S; Papademetriou V; Rutan G; Robins SJ;
Circulation; 2001 Jun; 103(23):2828-33. PubMed ID: 11401940
[TBL] [Abstract][Full Text] [Related]
10. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group.
Rubins HB; Robins SJ; Collins D; Fye CL; Anderson JW; Elam MB; Faas FH; Linares E; Schaefer EJ; Schectman G; Wilt TJ; Wittes J
N Engl J Med; 1999 Aug; 341(6):410-8. PubMed ID: 10438259
[TBL] [Abstract][Full Text] [Related]
11. Low-density lipoprotein and high-density lipoprotein particle subclasses predict coronary events and are favorably changed by gemfibrozil therapy in the Veterans Affairs High-Density Lipoprotein Intervention Trial.
Otvos JD; Collins D; Freedman DS; Shalaurova I; Schaefer EJ; McNamara JR; Bloomfield HE; Robins SJ
Circulation; 2006 Mar; 113(12):1556-63. PubMed ID: 16534013
[TBL] [Abstract][Full Text] [Related]
12. Effect of gemfibrozil treatment in sulfonylurea-treated patients with noninsulin-dependent diabetes mellitus.
Shen DC; Fuh MM; Shieh SM; Chen YD; Reaven GM
J Clin Endocrinol Metab; 1991 Sep; 73(3):503-10. PubMed ID: 1874929
[TBL] [Abstract][Full Text] [Related]
13. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study.
Downs JR; Clearfield M; Weis S; Whitney E; Shapiro DR; Beere PA; Langendorfer A; Stein EA; Kruyer W; Gotto AM
JAMA; 1998 May; 279(20):1615-22. PubMed ID: 9613910
[TBL] [Abstract][Full Text] [Related]
14. Relation of gemfibrozil treatment and high-density lipoprotein subpopulation profile with cardiovascular events in the Veterans Affairs High-Density Lipoprotein Intervention Trial.
Asztalos BF; Collins D; Horvath KV; Bloomfield HE; Robins SJ; Schaefer EJ
Metabolism; 2008 Jan; 57(1):77-83. PubMed ID: 18078862
[TBL] [Abstract][Full Text] [Related]
15. Cost effectiveness of treating low HDL-cholesterol in the primary prevention of coronary heart disease.
Hay JW; Sterling KL
Pharmacoeconomics; 2005; 23(2):133-41. PubMed ID: 15748088
[TBL] [Abstract][Full Text] [Related]
16. Influence of risk factors on peripheral and cerebrovascular disease in men with coronary artery disease, low high-density lipoprotein cholesterol levels, and desirable low-density lipoprotein cholesterol levels. HIT Investigators. Department of Veterans Affairs HDL Intervention Trial.
Papademetriou V; Narayan P; Rubins H; Collins D; Robins S
Am Heart J; 1998 Oct; 136(4 Pt 1):734-40. PubMed ID: 9778079
[TBL] [Abstract][Full Text] [Related]
17. High-density lipoprotein cholesterol as an independent risk factor in cardiovascular disease: assessing the data from Framingham to the Veterans Affairs High--Density Lipoprotein Intervention Trial.
Boden WE
Am J Cardiol; 2000 Dec; 86(12A):19L-22L. PubMed ID: 11374850
[TBL] [Abstract][Full Text] [Related]
18. The L162V polymorphism at the peroxisome proliferator activated receptor alpha locus modulates the risk of cardiovascular events associated with insulin resistance and diabetes mellitus: the Veterans Affairs HDL Intervention Trial (VA-HIT).
Tai ES; Collins D; Robins SJ; O'Connor JJ; Bloomfield HE; Ordovas JM; Schaefer EJ; Brousseau ME
Atherosclerosis; 2006 Jul; 187(1):153-60. PubMed ID: 16221474
[TBL] [Abstract][Full Text] [Related]
19. Fasting hyperinsulinaemia and 2-h glycaemia predict coronary heart disease in patients with type 2 diabetes.
Faghihi-Kashani S; Bonnet F; Hafezi-Nejad N; Heidari B; Aghajani Nargesi A; Sheikhbahaei S; Ebadi M; Esteghamati A
Diabetes Metab; 2016 Feb; 42(1):55-61. PubMed ID: 26531321
[TBL] [Abstract][Full Text] [Related]
20. Insulin resistance, beta cell function and cardiovascular risk factors in Ghanaians with varying degrees of glucose tolerance.
Amoah AG; Schuster DP; Gaillard T; Osei K
Ethn Dis; 2002; 12(4):S3-10-7. PubMed ID: 12477148
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
